Nexgram secured RM36 million Saliva-based Test kits Sales Contract [12 Aug 2021] Press Release

12 Aug 2021, Kuala Lumpur

Nexgram Holdings Berhad (Nexgram) wholly owned subsidiary Associate Partners Laboratories Sdn Bhd (APLab) secured RM36 million Covid-19 Antigen Nasal and Saliva Test kits procurement agreement with Covid-19 screening test kit distributor Ottigo Sdn Bhd (Ottigo).

The exclusive procurement contract conducted through Tracvirus Clinic System is expected to service the government and private customers of Nexgram and Ottigo, as part of both companies corporate social responsibility program. 

Besides supplying to government and corporate customers, Nexgram currently allow group purchase for Covid-19 Antigen Nasal and Saliva Test kits, as well as Covid-19 Vaccine Efficacy Antibody Test Kits with doctors assigned at Nexgram web portal

Priority is given to medical service providers servicing frontliners, essential industries, schools and construction sectors.

“ The ability to provide rapid, easy-to-use tests for different variants of SARS-CoV-2 could improve the tracking, treatment, and general response to the COVID-19 pandemic globally.”, quoted Tuan Haji Mazru, Nexgram Group Executive Director.

On the other hand, Nexgram Group also distribute MDA approved Covid-19 Vaccine Efficacy Antibody Test Kits, or the SARS-CoV-2 Neutralising Test (a.k.a Surrogate Virus Neutralization Antibody Detection) can evaluate the Covid-19 vaccine efficacy. This is a highly specific test that detects antibodies, which block the interaction between Spike-RBD domain of the virus and the ACE2 receptor on the human cell. Blocking that interaction can prevent the virus from entering and infecting the cells.

About Nexgram Biomedic Sdn Bhd (NBSB)

NEXGRAM BIOMEDIC GROUP is a global bio technology company dedicated to develop new medical devices, drugs, and technologies in support of innovations in the Healthcare field. The group subsidiaries include Medical Brands Inc and Tri-G Technologies Sdn Bhd (Tri-G) specialising in medical devices; VaccinesLab which conduct clinical trial and vaccine distribution; data science company MDS Data Science (M) Sdn Bhd which develops Covid-19 screening test and vaccine record tracking App using electronic health certificates (E-Certs) powered by Tracvirus Open Platform; NMed Industries Sdn Bhd which trade, distribute and invest in medical device and personal protection equipment manufacturing; Arita Group, the specialist in Acrylic medical devices material and vaccine bottling manufacturer; as well as Glove Alliance Sdn Bhd specialising in medical and disposable nitrile gloves end-to-end supply chain. 

APLab is a subsidiary of NBSB, the medical and biotechnology investment holding company of Nexgram Group. The company operates technology platform for medical device and supplies group purchase under just-in-time supply chain management system for medical groups, hospitals, GPs and healthcare companies. The company pandemic product distributorship includes Nasal Antigen Swab Test Kit, Saliva and Breath Antigen Test Kit, Vaccine Efficacy Antibody Test Kit and PCR solutions. The company held sole distributorships including patented one (1) hour RT-PCR swab Test solution for mobile laboratories and airports in Asian markets.

Tri-G is the service provider for government system TracAPM digital system, SafeTravelPass Malaysia, TracAPM Quarantine Hotel and Transport System, and Tracvirus Lab and Clinic System. The company is also the government TracAPM Covid-19 quarantine process management system provider under the brand of SafeTravelPass Malaysia for all quarantine entry-registration by all travellers coming into Malaysia. The TracAPM system is developed for the government of Malaysia, licensed and maintained by Tri-G, the sister company of NBSB, both subsidiaries of Nexgram. Tri-G is also MDA and medical device licenses company approved by Malaysia Ministry of Health.